

Funding

Targeted Therapies in Melanoma

Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: P01 (CA114046-03)
Years 5-10, Period: May 16, 2008 to October 1, 2018

The Role of Genetic Susceptibility in Melanoma Development

Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: R01 (CA182890)
Years 1-5, Period: May 1, 2014 to April 30, 2019

SPORE in Skin Cancer

Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: SPORE (P50 CA174523)
Years 1-5, Period: September 16, 2014 to September 15, 2019

Understanding the Immune-Biology of Checkpoint Inhibitors to Develop New Strategies for Therapy

Principal Investigator: Meenhard Herlyn
Agency: Department of Defense – PRCRP
Type: CA150619- W81XWH-16-1-0119
This proposal deals with the development of novel treatment strategies for the deadliest of all skin cancers, melanoma. The core of the proposal is a clinical trial for the treatment of advanced melanoma, in which two newly-approved drugs are tested in combination when compared to the stronger drug alone.
Years 1-3, Period: September 30, 2016 to September 29, 2019

Overcoming Drug Resistance to Kinase Inhibitors with Immune Checkpoint Inhibitors

Principal Investigator: Meenhard Herlyn
Agency: Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Type: N/A
Period: 2007-Present

Targeted Therapies in Melanoma – Diversity Supplement Program

Principal Investigator: Meenhard Herlyn
Agency: NIH/NCI
Type: 3 P01 CA 114046-09S1

Support for post-baccalaureate position for Ms. Cynthia Chude, a degree holder from the University of Massachusetts Dartmouth, pursuing research training in health-related sciences with the goal of admission to an MD/PhD program. She will participate in the program for two years to get a publication and skills needed to succeed in an MD/PhD program. NOTE: Support of a research specialist in R. Amaravadi lab at UPENN.
Period: September 1, 2016 to August 31, 2018